When "Standard of Care" Isn't Caring Enough: A New Hope for Metastatic Colorectal Cancer

Most people assume that once you've exhausted two lines of chemotherapy for metastatic colorectal cancer, your remaining options are basically a choice between "meh" and "slightly worse than meh." Turns out, they might be wrong.

A new phase 2 trial just dropped some numbers that made oncologists do a double-take, and for once, the hype might actually be justified. Let me explain why this matters—and why I'm cautiously optimistic instead of reflexively eye-rolling at another "breakthrough."

The Problem with Third-Line Treatment (Spoiler: It's Not Great)

Here's the uncomfortable truth about metastatic colorectal cancer that's already burned through oxaliplatin and irinotecan-based regimens: your options shrink faster than a tumor on a good day. Regorafenib, the current standard, offers a median progression-free survival of about 2 months. Two months. That's roughly the shelf life of leftover holiday cookies.

Regorafenib isn't useless—it received FDA approval because it does something—but "something" and "meaningful" aren't always synonyms. The bar, frankly, has been sitting on the floor.

Enter the Adenosine Pathway (Your Tumor's Secret Weapon)

Cancer cells are sneaky little operators. One of their favorite tricks involves adenosine, a molecule that essentially tells your immune system to take a nap. Tumors pump out adenosine like a college student pumps out excuses during finals week, creating a microenvironment where T-cells show up to the party but can't actually do anything useful.

Etrumadenant blocks the A2a and A2b receptors that respond to this adenosine signal. Think of it as giving your immune cells noise-canceling headphones so they can ignore the tumor's "please don't kill me" broadcast.

The ARC-9 Trial: What Actually Happened

The study randomized 112 patients to receive either the combination therapy (etrumadenant plus zimberelimab, an anti-PD-1 antibody, plus FOLFOX chemotherapy, plus bevacizumab—let's call it EZFB because life is short) or regorafenib alone.

The results? Progression-free survival jumped from 2.1 months with regorafenib to 6.2 months with EZFB. That's nearly triple. The hazard ratio of 0.27 is the kind of number that makes statisticians spill their coffee.

But here's where it gets genuinely interesting: overall survival went from 9.5 months to 19.7 months. We're talking about doubling the time patients lived. In a third-line setting. For a cancer that historically laughs at third-line treatments.

The Catch (Because There's Always a Catch)

Before we start planning the victory parade, let's acknowledge reality. This was a phase 2 trial with 112 patients. Phase 2 trials are where promising therapies go to show off before the harsh reality of phase 3 either confirms or crushes our hopes.

The side effect profile was also more intense with EZFB—82% experienced grade 3 or higher adverse events compared to 49% with regorafenib. However, and this is important, only 5% of EZFB patients discontinued treatment due to side effects versus 17% on regorafenib. More side effects, but apparently more tolerable or manageable ones.

The overall response rate of 17% versus 3% sounds impressive until you remember that 17% still means 83% of patients didn't see their tumors shrink meaningfully. This isn't a cure; it's a better option than what we had.

Why This Actually Matters

The adenosine pathway has been a tantalizing target for years, but translating laboratory excitement into clinical benefit has proven frustratingly difficult. This trial suggests we might finally be cracking that code—at least in this specific context.

Combining adenosine receptor blockade with PD-1 inhibition, chemotherapy, and anti-angiogenic therapy addresses multiple tumor defense mechanisms simultaneously. It's like attacking a fortress from four directions instead of one. The fortress might still hold, but it's going to have a much harder time.

For patients who've watched their treatment options dwindle, this represents something genuinely meaningful: time. Not infinite time, not a cure, but substantially more time than the current standard offers.

The Bottom Line

Color me cautiously impressed. These results need confirmation in larger trials, and we need to understand which patients benefit most. But in a space where incremental improvements are celebrated, doubling overall survival is anything but incremental.

Sometimes the skeptic gets to be pleasantly surprised.

References:

1. Cecchini M, Han SW, Lee S, et al. The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer. Clin Cancer Res. 2025. DOI: 10.1158/1078-0432.CCR-25-3727. PMID: 41870279

2. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312. DOI: 10.1016/S0140-6736(12)61900-X. PMID: 23177514

3. Sitkovsky MV, Hatfield S, Abbott R, et al. Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res. 2014;2(7):598-605. DOI: 10.1158/2326-6066.CIR-14-0075. PMCID: PMC4090623

4. Willingham SB, Ho PY, Hotson A, et al. A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models. Cancer Immunol Res. 2018;6(10):1136-1149. DOI: 10.1158/2326-6066.CIR-18-0056. PMID: 30131376

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.